ARCT

Company Overview — What Does Arcturus Therapeutics Holdings Inc. Do?

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics Holdings Inc. (ARCT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joseph E. Payne and employs approximately 180 people. With a market capitalization of $223M, ARCT is one of the notable companies in the Healthcare sector.

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Rating — Reduce (April 2026)

As of April 2026, Arcturus Therapeutics Holdings Inc. receives a Reduce rating with a composite score of 26.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ARCT ranks #3,251 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Arcturus Therapeutics Holdings Inc. ranks #492 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARCT Stock Price and 52-Week Range

Arcturus Therapeutics Holdings Inc. (ARCT) currently trades at $8.23. The stock gained $0.01 (0.1%) in the most recent trading session. The 52-week high for ARCT is $24.17, which means the stock is currently trading -65.9% from its annual peak. The 52-week low is $5.85, putting the stock 40.7% above its annual trough. Recent trading volume was 373K shares, suggesting relatively thin trading activity.

Is ARCT Overvalued or Undervalued? — Valuation Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.13x, versus the sector average of 2.75x. The price-to-sales ratio is 2.08x, compared to 1.66x for the average Healthcare stock.

At current multiples, Arcturus Therapeutics Holdings Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Arcturus Therapeutics Holdings Inc. Profitability — ROE, Margins, and Quality Score

Arcturus Therapeutics Holdings Inc. (ARCT) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -20.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -16.1% versus the sector average of -33.1%.

On a margin basis, Arcturus Therapeutics Holdings Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -55.1% (sector: -66.1%). Net profit margin stands at -43.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -65.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARCT Debt, Balance Sheet, and Financial Health

Arcturus Therapeutics Holdings Inc. has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.64x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $180M.

ARCT has a beta of 1.66, meaning it is more volatile than the broader market — a $10,000 investment in ARCT would be expected to move 66.0% more than the S&P 500 on any given day. The stability factor score for Arcturus Therapeutics Holdings Inc. is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Arcturus Therapeutics Holdings Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Arcturus Therapeutics Holdings Inc. reported revenue of $117M and earnings per share (EPS) of $-2.40. Net income for the quarter was $-44M. Gross margin was 100.0%. Operating income came in at $-56M.

In FY 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $82M and earnings per share (EPS) of $-2.40. Net income for the quarter was $-66M. Revenue grew -46.1% year-over-year compared to FY 2024. Operating income came in at $-76M.

In Q3 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $17M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-13M. Revenue grew -58.8% year-over-year compared to Q3 2024. Operating income came in at $-17M.

In Q2 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $28M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-9M. Revenue grew -43.2% year-over-year compared to Q2 2024. Operating income came in at $-12M.

Over the past 8 quarters, Arcturus Therapeutics Holdings Inc. has demonstrated a growth trajectory, with revenue expanding from $50M to $117M. Investors analyzing ARCT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARCT Dividend Yield and Income Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARCT Momentum and Technical Analysis Profile

Arcturus Therapeutics Holdings Inc. (ARCT) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

ARCT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Arcturus Therapeutics Holdings Inc. (ARCT) ranks #492 out of 838 stocks based on the Blank Capital composite score. This places ARCT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARCT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARCT vs S&P 500 (SPY) comparison to assess how Arcturus Therapeutics Holdings Inc. stacks up against the broader market across all factor dimensions.

ARCT Next Earnings Date

No upcoming earnings date has been announced for Arcturus Therapeutics Holdings Inc. (ARCT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARCT? — Investment Thesis Summary

The quantitative profile for Arcturus Therapeutics Holdings Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. High volatility (stability score 20/100) increases portfolio risk.

In summary, Arcturus Therapeutics Holdings Inc. (ARCT) earns a Reduce rating with a composite score of 26.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARCT stock.

Related Resources for ARCT Investors

Explore more research and tools: ARCT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARCT head-to-head with peers: ARCT vs AZN, ARCT vs SLGL, ARCT vs VMD.